Cargando…
The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The uniq...
Autores principales: | Taheri, Yasaman, Joković, Nataša, Vitorović, Jelena, Grundmann, Oliver, Maroyi, Alfred, Calina, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898678/ https://www.ncbi.nlm.nih.gov/pubmed/33628170 http://dx.doi.org/10.3389/fphar.2020.578823 |
Ejemplares similares
-
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Wang, Chuanhai, et al.
Publicado: (2022) -
Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Frontiers Production Office,
Publicado: (2022) -
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
por: Sarkar, Chandan, et al.
Publicado: (2020) -
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021) -
Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action
por: Sharifi-Rad, Javad, et al.
Publicado: (2020)